ViaDerma, Inc. announced TetraStemTM, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Due to mutations of historically more common forms of staph infections, according to the Mayo Clinic, certain strains of staph bacteria have become resistant to the antibiotics commonly used to treat staph infections.

Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.